Abstract
Chordoma is a rare and invasive malignant tumor which primarily relies on surgical treatments. Anticipation of its recurrence and patient survival longevity has been a critical issue of the treatments. This retrospective study examined the survivin expression of sacral chordoma in 30 patients undergoing surgery in our hospital from January 2000 to July 2010, and compared it with chordoma recurrence. Survivin expression was 70 % positive in 30 patients. The positive expression of survivin with recurrence was significantly higher than that without recurrence (p = 0.017) and was inversely related to the continuous disease-free survival time (p < 0.001). Survivin expression was associated with recurrence. The correlation suggested that the survivin expression could be used as an independent predictor of recurrence and could be a potential bio-target gene of angiogenesis in sacral chordoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12(1):1–11.
Chandawarkar RY. Sacrococcygeal chordoma: review of 50 consecutive patients. World J Surg. 1996;20(6):717–9.
Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87(10):2211–6.
Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326(23):1514–21.
Yang HL, Zhu LF, Liu JY, et al. Surgical treatment of sacral chordomas with preoperative arterial embolization and prognostic indicators of outcome. Spine J. 2007;5(7):34S.
Guzman JR, Fukuda S, Pelus LM. Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2. Gene Ther Mol Biol. 2009;13B:264–73.
Chiou SK, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):PI25–9.
Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol. 2001;158(5):1757–65.
Lu CD, Altieri DC, Tanigawa N. Expression of a novel anti-apoptosis gene, Survivin, correlated with tumor cell apoptosis and P53 accumulation in gastric carcinomas. Cancer Res. 1998;58(9):1808–12.
Naka T, Boltze C, Samii A, et al. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98(9):1934–41.
Favre J, Deruaz JP, Uske A. Skull base chordomas: presentation of six cases and review of the literature. J Clin Neurosci. 1994;1(l):7–18.
Hulen CA, Temple HT, Fox WP, et al. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. 2006;88(7):1532–9.
Hanna SA, Aston WJ, Briggs TW, et al. Sacral chordoma: can local recurrence after sacrectomy be predicted ? Clin Orthop Relat Res. 2008;466(9):2217–23.
Miettinen M, Lehto VP, Virtanen I. Malignant fibrous histiocytoma within a recurrent chordoma. A light microscopic, electron microscopic, and immunohistochemical study. Am J Clin Pathol. 1984;82(6):738–43.
Chen KW, Yang HL, Lu J, et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neuro Oncol. 2011;101(3):357–63.
Chen KW, Yang HL, Lu J, et al. Risk factors for postoperative wound infections of sacral chordoma after surgical excision. J Spinal Disord Tech. 2011;24(4):230–4.
Hanna SA, Aston WJ, Briggs TW, et al. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466:2217–23.
Olie RA, Simões-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces and sensitizes apoptosis lung cancer cell to chemotherapy. Cancer Res. 2000;60(11):2805–9.
Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–20.
Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004;50:1986–93.
Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599–607.
Simpson AH, Porter A, Davis A, et al. Cephalad sacral resection with a combined extended ilioinguinal and posterior approach. J Bone Joint Surg Am. 1995;77(3):405–11.
Sundaresan N, Galicich JH, Chu FC, et al. Spinal chordomas. J Neurosurg. 1979;50:312–9.
Acknowledgments
This study was supported by the National Natural Science Foundation of China under Grant No. 31270995 and 11072165.
Conflict of interest
The authors declare that there are no conflicts of interest.
Ethical standard
This study was approved by Soochow university ethics committee.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chen, C., Yang, HL., Chen, KW. et al. High expression of survivin in sacral chordoma. Med Oncol 30, 529 (2013). https://doi.org/10.1007/s12032-013-0529-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-013-0529-4